Abstract The prevalence of overweight and obesity is strikingly increasing worldwide. Obesity is a major risk factor for non-insulin-dependent diabetes mellitus, cardiovascular diseases, and cancer, and is also associated with various psychosocial consequences. Menopausal transition is associated with unfavorable changes in body composition and abdominal fat deposition, which is accompanied by an increment of insulin resistance/hyperinsulinemia, a decrease in sex hormone-binding globulin levels and, consequently, an increase in free testosterone and greater androgenicity. Central body fat also correlates with deleterious changes in adipokines and inflammation markers like leptin, C-reactive protein, and adiponectin. In addition, the greater deposition of visceral fat in the menopausal transition contributes to the development of an atherogenic lipoprotein profile, which includes high triglyceride and low high-density lipoprotein (HDL) cholesterol concentrations, as well as an increment of small dense low-density lipoprotein (LDL) subfraction, intermediate density lipoproteins (IDL), apolipoprotein (apo) B/apo A-I ratio and lipoprotein(a).
Introduction
Obesity is the most prevalent nutrition-related disorder in Western countries, and the prevalence of overweight and obesity is increasing worldwide at an alarming rate [1], affecting both developed and developing countries. In the past 20 years, the rates of obesity increased significantly in developing countries that adopted a Western lifestyle, involving decreased physical activity and overconsumption of cheap, energy-dense food. At least 1 billion people worldwide are thought to be overweight (body mass index [BMI] 25-29.9 kg/m 2 ) or obese (BMI≥30 kg/m 2 ); at least 300 million people are thought to be obese [1] while one-third of the population is overweight.
The health consequences of obesity are many and varied, ranging from an increased risk of premature death to several nonfatal diseases with adverse impact on quality of life. Obesity is a major risk factor for non-insulin-dependent diabetes mellitus, cardiovascular diseases (CVD) (heart disease, stroke, and hypertension), and cancer [1] , and is also associated with various psychosocial consequences.
Although increasing BMI is a powerful predictor of metabolic disease risk, individuals with the same BMI may have greatly different amounts of visceral (central or abdominal) fat, the adipose tissue depot known to be associated with the greatest metabolic risk [2, 3] . Abdominal obesity, when accompanied by metabolic derangements, including insulin resistance, low high-density lipoprotein cholesterol (HDL-C), elevated triglycerides (TG), and raised blood pressure, significantly increases the predicted cardiovascular disease risk [4] and constitutes the well-known metabolic syndrome. Insulin resistance and inflammation are the two more common abnormalities that link obesity with adverse metabolic changes [5, 6] .
The rapid increases in overweight and obesity are multifactorial and only partly attributable to changes in lifestyle practices [7] . The prevalence of obesity is typically higher in females than males globally. While the reasons for this sex difference in obesity are not clear, fluctuations in female sex hormones at menarche, pregnancy, and menopause may play a role in the adipose tissue expansion. Moreover, weight gain, with an increase in body fat percentage and a concomitant redistribution of fat accumulation from peripheral locations toward increased intra-abdominal depots, is common after the menopause [8, 9] . This timing suggests that the female sex steroid pattern is important in adipose tissue metabolism and highlights the role of sex hormones on fat distribution, a fact that has been extensively reported [10, 11] .
The menopause transition begins with the onset of the first menstrual irregularity and ends with cessation of menses [12] . Concerning estradiol levels in this period of life, they are frequently higher than those found in premenopausal women [13, 14] , but, indeed, estradiol concentrations in perimenopausal women show a high degree of variability [13] . In turn, changes in androgen levels during the menopausal transition are controversial, although it is generally accepted that testosterone levels do not change significantly in this period of life [15] . Given that alterations of the hormonal profile begin in the early 40s, in the menopausal transition, consequently, changes in risk factors for CVD (such as anthropometric characteristics) could also be observed in this period. It has been necessary to investigate the behavior of these factors during the transition to menopause and it is still not clear when metabolic alterations occur. Different studies have shown that menopausal transition is associated with unfavorable changes in body composition and abdominal fat deposition [9, 15, 16] .
This review summarizes and discusses the impact of abdominal obesity and the metabolic alterations associated with the menopausal transition.
Sex Hormones and Abdominal Obesity
Estrogens Data in the literature suggest that estrogens play an important role in regulating body fat distribution in women. In a longitudinal study, Lovejoy et al. [17] showed that visceral adipose tissue increased significantly through the menopausal transition from 3-4 years before menopause, and this increment in abdominal fat paralleled the decrease in serum estradiol over time.
Taking into account BMI changes and body fat distribution with declining estrogen levels, several mechanisms have been proposed in relation to alterations in adipose tissue metabolism. It has been described that during the premenopausal period, lipid deposition in gluteofemoral adipocytes is facilitated by lipoprotein lipase (LPL) via estrogen action to assure adequate energy stores for reproduction [18] . This LPL activity in gluteofemoral adipocytes is higher than that of abdominal adipocytes. On the other hand, in postmenopausal women, femoral adipose tissue shows low LPL activity, while in the abdominal region, there is increasing visceral fat deposition and higher lipolytic activity [19] . These changes become evident since the menopausal transition.
Trying to explain how estrogen promotes and maintains the typical female type of fat distribution, Pedersen et al. [20] studied the effects of estradiol in vivo and in vitro on human adipose tissue metabolism and observed that estradiol administration attenuates lipolytic response in subcutaneous abdominal adipocytes, but not in intra-abdominal adipocytes. They found that estradiol directly increases the number of antilipolytic α-2A-adrenergic receptors in subcutaneous adipocytes and, in contrast, no effect of estrogen on α-2A-adrenergic receptor messenger RNA expression was observed in adipocytes from the visceral fat depots. In other words, estrogen seems to inhibit lipolysis only in subcutaneous depots; consequently, they preferentially stimulate fat storage in subcutaneous versus intra-abdominal fat tissue.
Other authors showed that postmenopausal women under estrogen replacement therapy have significantly lower waist-to-hip ratio [21] and less visceral adipose tissue [22] compared with estrogen non-users.
In a study of women transitioning to menopause, we observed an inverse trend between estradiol levels and waist circumference, a marker of abdominal fat [16] . As it was said above, during menopausal transition, estradiol levels in each woman greatly fluctuate until they decrease completely in postmenopause [13] . This variability could explain why we did not find a strong correlation between this hormone and waist circumference.
Androgens/Testosterone
There is evidence in the literature that increased testosterone and decreased sex hormone-binding globulin (SHBG) levels are strongly associated with central adiposity. Janssen et al. [23] , in a 9-year longitudinal study of a multiethnic cohort undergoing the menopausal transition, showed that bioavailable testosterone, but not estradiol, was strongly related to waist circumference. Furthermore, in multivariate models, the relationship of SHBG to waist circumference was similar to that of bioavailable testosterone. Other authors also found that the major hormonal change associated with central adiposity during the menopausal transition was the increase in the free testosterone index [24] , independent of age and estradiol levels. This decrease in SHBG and subsequent increase in free testosterone may act directly on fat stores or may modify expression of genes controlling adipocyte differentiation and metabolism.
In a cross-sectional study, our group evaluated the relationship between androgens and cardiovascular risk factors in the menopausal transition [15] . We found an increment in the androgenic milieu that correlated with abdominal fat, insulin-resistance, and atherogenic lipoproteins. According to Janssen et al. [23] , the significant correlation between waist circumference and SHBG persisted after a multiple regression analysis with waist circumference as the independent variable.
More recently, Janssen et al. [25••] suggest that testosterone is a strong predictor of visceral fat and, as such, associated with higher cardiovascular risk in women transitioning through menopause. As estradiol production decreases with the proximity of menopause, SHBG levels decline, and thus, the proportion of bioavailable testosterone increases. Dieudonné et al. [26] demonstrated the presence of androgen receptors in the nuclear and cytosolic fractions of human preadipocytes, a decrease of androgen receptor expression during adipogenesis, and an upregulation of these receptors by androgens in vitro. These findings can explain visceral fat accumulation regulated by bioavailable testosterone.
Alternatively, in postmenopause, body mass increment correlates with insulin resistance and hyperinsulinemia, and both situations determine a decrease in SHBG levels and, consequently, an increase in free testosterone and greater androgenicity, all these changes being reflected in higher central adiposity [18] (Fig. 1) . In the study of Janssen et al. [25••] , the association between visceral fat and bioavailable testosterone persisted when both estradiol and insulin resistance were included in the model; therefore, they concluded that the effect of bioavailable testosterone on visceral fat is only partially mediated by insulin resistance.
It has been suggested that these changes begin in the menopausal transition, and therefore, we propose that evaluation of CVD risk in women in this period of life should include androgens, considering abdominal obesity as one of the main determinants of the relation between androgenic parameters and CVD risk factors.
Effect of Hormonal Alterations on Adipokines

Leptin/adiponectin
Adipose tissue is nowadays considered an important endocrine and paracrine organ that produces several proinflammatory substances [27] that contribute to vascular injury, insulin resistance, and atherogenesis. These adipokines include: tumor necrosis factor (TNF)-α, interleukin (IL)-6, leptin, plasminogen activator inhibitor (PAI)-1, angiotensinogen, resistin, and C-reactive protein (CRP). Some of them have a protective role against vascular inflammation and insulin resistance, such as adiponectin and nitric oxide, among others.
Leptin is a 167-amino acid hormone secreted largely by adipose tissue that controls food intake and energy expenditure. Other potential physiological roles for leptin have been described, like its action in the immune and reproductive systems [27] .
Leptin concentrations have been reported to be up to four times higher in women than in men [28] [29] [30] , associated with the higher body fat content observed in women [31] . Estrogen increases leptin concentration [32] , which also correlates to adipose distribution and adipocyte size in women but not in men [28, 30] . Different studies have shown that leptin levels increase during the menopausal transition [33, 34] , but in postmenopausal women, others found that the increase in leptin levels is associated with aging and not with menopausal status [35] . Furthermore, Hadji et al. [36] showed that neither menopause nor serum estradiol alters plasma leptin concentration, even after controlling for BMI. They found that serum leptin concentrations were significantly higher in pre-and postmenopausal obese women, compared with normal-weight control patients, so only BMI remained as a statistically significant independent predictor for leptin.
Adiponectin belongs to the cytokines secreted by adipose tissue and it is inversely associated with obesity and inflammation. Women present higher circulating levels of adiponectin than men [37] . While some studies showed no differences in adiponectin concentrations between pre-and perimenopausal women [33, 34] , others showed them increased in postmenopause [38••] . Sowers et al. [33] reported that mean adjusted adiponectin levels were lower in women during their perimenopausal stage relative to their pre-or postmenopausal stages in both obese and nonobese women, and those differences persisted after adjusting for the covariates.
In reference to most of the adipokines, Ritland et al. [39] observed that centralized body fat was the main contributor to each circulating appetitive hormone in healthy postmenopausal women: androidal-to-gynoidal fat mass ratio (adiponectin), android fat mass (leptin), sagittal abdominal diameter (insulin), or waist circumference (ghrelin) ghrelin. 
Risk Factors Associated with Abdominal Obesity
Even though most theories consider insulin resistance as the prime factor linking visceral obesity with adverse metabolic changes [40] , several studies suggest that other factors like dyslipidemia and chronic systemic inflammation have a main role in vascular disease risk [41, 42] .
Insulin Resistance/Hyperinsulinemia
Abdominal obesity is a highly prevalent feature of the insulin resistant state; however, the mechanisms by which they are related are not fully understood. Analysis of abdominal obesity by imaging studies have generally reached the conclusion that it is the excess of intra-abdominal or visceral adipose tissue and not the amount of subcutaneous abdominal fat which is the key correlate of the metabolic abnormalities observed in overweight/obese patients [43] . Multiple environmental and genetic factors are thought to influence the manifestation of abdominal obesity. Intraabdominal fat increases with age in both overweight and normal-weight individuals, independently of changes in total body fat [44] . In premenopausal women, Ross et al. [45] have observed that individuals matched for subcutaneous abdominal adiposity, but with either a low versus a high accumulation of visceral adipose tissue, were markedly different in their levels of insulin resistance and glucose tolerance. However, after being matched for visceral adiposity, individuals with low or high levels of subcutaneous fat were found not to differ in insulin sensitivity [45] .
The expanded adipose tissue contributes to expose the liver to high concentrations of free fatty acids (FFA), impairing several hepatic metabolic processes leading to hyperinsulinemia [4] . On the other side, there is an increase in the secretion of different adipokines, such as IL-6 and TNF-α, which also contributes to the insulin-resistant state.
The World Health Organization MONICA (Multinational Monitoring of Trends and Determinants in Cardiovascular Disease) Project, monitoring CVD in 21 countries, suggested that the relationship between insulin concentration and coronary heart disease was potentially stronger in women than in men [46] . In addition, obesity development is accelerated after menopause; factors such as loss of estrogens, the aging process, and changes in lifestyle all may be contributors [47, 48] .
In fact, the increase in insulin resistance observed in postmenopause by many authors [49] could be explained not only by the menopause effect, but also by aging and abdominal obesity [8, 50] . Given the difficulties in the assessment of insulin resistance by the standard methods, for epidemiologic and clinical studies, more simple and indirect methods have been advocated [9] . The frequency of insulin resistance increases from the time of the menopausal transition to the postmenopause. A study of ours [9] showed that the prevalence of the metabolic syndrome rises from the earlier stages of the menopausal transition, without differences with postmenopausal women, while it was not detected in the premenopausal group.
Dyslipidemia
Some authors have observed that age and menopause both can influence the changes in body fat distribution [9, 51] and that, in turn, central obesity contributes to the impairment of the lipoprotein profile.
High visceral adipose tissue accumulation has been associated with a deteriorated metabolic profile such as high TG and low HDL-C concentrations in postmenopausal women [8, 9, 16] . The association between visceral adipose tissue accumulation and deteriorated metabolic profile may be explained in part by high lipolytic action of visceral adipose tissue, leading to an increased flux of FFA in portal circulation to liver that increases intracellular availability of TG and stimulates the assembly and secretion of very lowdensity lipoprotein (VLDL) particles. Moreover, in postmenopausal women (PMW), an adverse lipoprotein pattern has been described, even though HDL-C levels tend to be maintained or slightly decreased [16, 52] . In turn, hepatic lipase is a key enzyme involved in the hydrolysis of TG and phospholipids contained in low-density lipoprotein (LDL) and HDL particles, and, in cooperation with cholesteryl ester transfer protein (CETP), it also contributes to lipoprotein remodeling. We previously reported a high hepatic lipase activity in menopause [53] , likely associated with the fall of endogenous estrogens. A consequence of higher hepatic lipase activity may be the increase of small dense LDL subfraction, already described in PMW [8, 54] . This particle per se has a greater atherogenic potential than other LDL subclasses [55] .
The high proportion of this atherogenic subfraction leads to an enhanced passage of these particles through the endothelium allowing their binding to proteoglycans, given that small dense LDL have greater affinity than large buoyant LDL [55] . Results from studies on women with clinical and subclinical disease showed that small dense LDL was related to high incidence of coronary heart disease among older women [56] . It can be suggested that the higher small dense LDL proportion is the higher LDL oxidability. Moreover, the higher abdominal fat accumulation measured as waist circumference is the higher LDL oxidability. Therefore, women with high degree of insulin resistance would present an increase in small dense LDL proportion and LDL susceptibility to oxidation [52] .
In reference to the presence of remnants of lipoproteins, we have described an increase in intermediate-density lipoproteins (IDL) since the menopausal transition [16] as well as in PMW [53] . These remnants are highly associated with CVD, especially in women [57] . Given their small size, they can cross the endothelium, and in the subendothelium are considered modified lipoproteins and are phagocytosed by macrophages [58] . The increase in remnants of lipoproteins has been highly associated with abdominal obesity [50] .
Apolipoprotein (apo) B and the apo B/apo A-I ratio also has been described to be increased in PMW. The former is considered a useful risk marker with high predictive value because each atherogenic lipoprotein particle contains only one copy of apo B [59] . The ratio of apo B/apo A-I reflects the balance between pro-and antiatherogenic lipoproteins through their structural apolipoproteins, and this ratio has been demonstrated to be a strong predictor of acute myocardial infarction in men and women [60] . This ratio is also increased in PMW and correlates with the higher abdominal obesity [52] .
Another modified lipoprotein that is also increased since the menopausal transition is Lipoprotein(a), or Lp(a) [16] , which is greatly associated with CVD in women [61] . Estrogens have been shown to decrease Lp(a) synthesis, and the decrease in estrogens since the late menopausal transition would condition the increase in this lipoprotein (Fig. 2) .
Inflammation
An important issue in understanding obesity is the concept that it is characterized by a state of chronic low-grade inflammation [62] . While the general assumption is that inflammation is a consequence of obesity, it has been suggested that obesity, in fact, is a result of inflammatory disease [63] . Adipose tissue secretes factors that stimulate the production of inflammatory markers from the liver and other organs, and the adipocytes themselves are the immediate source of most of these inflammatory markers [62] . Visceral adipose tissue from obese patients also has been found to secrete higher levels of PAI-1, IL-6, TNF-α, and leptin and lower levels of adiponectin compared with lean patients [64] [65] [66] . Circulating inflammatory markers elevated in obese patients include CRP and serum amyloid A (SAA) [67, 68] .
In vitro and animal studies indicate that CRP may actively participate in plaque development by promoting endothelial dysfunction, monocyte adhesion to the endothelium, macrophage cholesterol accumulation, and fibrin breakdown (reduced plaque stability) increasing cardiovascular risk [69] .
The increase in visceral adiposity across the menopausal transition may result in the development of proinflammatory adipokine changes. Lee et al. [38• •] studied 69 healthy women who were followed up longitudinally from premenopausal to postmenopausal status. They found that SAA, monocyte-chemotactic protein-1 (MCP-1), tissue plasminogen activator antigen (tPA), and adiponectin levels increased significantly between the two measurement occasions. The increase in intra-abdominal fat was positively correlated with changes in leptin, tPA, SAA, and CRP levels and negatively correlated with the change in adiponectin. These findings suggest that the increase in visceral adiposity across the menopausal transition results in adverse effects on adipokine and inflammation levels.
We have previously discussed the behavior of leptin and adiponectin (this last one considered today as an inflammatory marker itself) in perimenopausal women and PMW. However, the most common and accepted inflammatory marker is CRP. Perry et al. [70] observed that androidal fat mass contributed to CRP and fibrinogen [70] , but showed no relationship to cytokines. This may suggest that, in healthy PMW, acute-phase proteins may be used as earlier indicators of CVD risk than inflammatory cytokines.
Studies by Miksztowicz et al. [71] and Muzzio et al. [72• •] revealed higher levels of high-sensitivity CRP in premenopausal women and PMW with metabolic syndrome and in healthy PMW, respectively, and this biomarker was associated with other risk factors like metalloproteinases and small dense LDL. Lee et al. [38••] reported that CRP, IL-6, and TNF-α did not change across the menopausal transition; however, CRP directly correlated with abdominal fat.
Conclusions
Different studies have shown that menopausal transition is associated with unfavorable changes in body composition LDL Fig. 2 Hepatic lipase behavior in postmenopause and insulinresistance conditions. After the increase in triglyceride (TG) levels, low-(LDL) and high-density lipoprotein (HDL) are enriched in TG and are better substrates for hepatic lipase. In postmenopause, there is an increase in the activity of hepatic lipase, promoting the predominance of small and dense LDL and of smaller HDL. VLDL very low-density lipoprotein; EC esterified cholesterol; sd LDL small dense low-density lipoprotein and abdominal fat deposition. The conjunction of higher free testosterone levels, lower SHBG, and an increase in insulin resistance contributes to an increment of visceral fat. This increase in abdominal adiposity across the menopausal transition is also associated to an unfavorable lipoprotein profile and also may result in adverse effects on adipokines and inflammation levels.
Women transitioning to menopause should consider adopting beneficial changes in lifestyle to prevent the development of abdominal obesity and, consequently, type 2 diabetes and CVD.
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